 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIA has officially enrolled its first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. 